Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
01:50pm, Friday, 31'st Jan 2025
JOURNAVX, a non-opioid analgesic, shows significant promise in treating pain with a superior safety profile, addressing a critical unmet need compared to opioids with FDA approval just announced. Vert
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
12:01pm, Friday, 31'st Jan 2025
The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
FDA approves a new painkiller for the first time in decades
11:39am, Friday, 31'st Jan 2025
Vertex Pharmaceuticals' non-opioid painkiller comes without the potential risk of addiction. Transcript: Conway Gittens: Wall Street heads into the weekend with modest strength - and that's no small f
Biotech Stock Rises After FDA Approves Non-Opioid Painkiller
11:18am, Friday, 31'st Jan 2025
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug Administration (FDA) approved the biotech's new non-opioid painkiller, Journavx.
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
10:36am, Friday, 31'st Jan 2025
Shares of Vertex Pharmaceuticals (VRTX) surged Friday, a day after the drugmaker reported federal regulators have approved its non-opioid painkiller, the first such drug to head to market in two decad
Vertex Pharmaceuticals CEO on non-opioid painkiller: It's safe, effective and non-addictive
10:33am, Friday, 31'st Jan 2025
CNBC's Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the FDA's approval of the company's non-opioid painkiller pill Journavx, a new
What's Happening With VRTX Stock?
09:32am, Friday, 31'st Jan 2025
Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can potent
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
06:59am, Friday, 31'st Jan 2025
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.
FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
06:52am, Friday, 31'st Jan 2025
CNBC's Becky Quick reports on the latest news.
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
04:35am, Friday, 31'st Jan 2025
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug Administration approved the company's non-opioid pain treatment.
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
02:00am, Friday, 31'st Jan 2025
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene
FDA Approves Non-Opioid Painkiller With No Addiction Risk
07:55pm, Thursday, 30'th Jan 2025
The Food and Drug Administration approved Vertex Pharmaceuticals' “Journavx” on Thursday, greenlighting the non-opioid painkiller for treating moderate to severe pain in what the FDA considered th
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller
07:04pm, Thursday, 30'th Jan 2025
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
06:25pm, Thursday, 30'th Jan 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid
